AbbVie’s Elahere Delivers 66% ORR but No PFS Gain in Platinum-Sensitive Ovarian Cancer
ABBV•AbbVie’s Elahere plus carboplatin achieved a 66.2% ORR versus 32.8% for platinum chemotherapy in Phase II MIROVA but failed to extend median PFS (9.53 vs 9.79 months; HR 1.0; p=0.996). The primary endpoint miss delays platinum-sensitive label expansion despite $690m 2025 sales and projected $2.6bn by 2032.
1. MIROVA Trial Results
The Phase II MIROVA trial evaluated Elahere plus carboplatin against investigator’s choice platinum chemotherapy in FRα-high platinum-sensitive ovarian cancer. While the Elahere combination achieved a confirmed ORR of 66.2% versus 32.8% with chemotherapy, it failed to extend median PFS (9.53 vs 9.79 months; HR 1.0; p=0.996), missing the trial’s primary endpoint.
2. Study Design and Patient Outcomes
MIROVA enrolled recurrent platinum-sensitive ovarian cancer patients with ≥75% FRα expression via companion diagnostic and randomized them to Elahere plus carboplatin followed by Elahere maintenance or standard platinum therapy followed by PARP inhibitor maintenance. Safety analyses showed consistent tolerability but higher rates of neuropathy and ocular adverse events in the Elahere arm compared with chemotherapy alone.
3. Commercial Implications and Outlook
Elahere generated $690 million in global sales in 2025 and was projected to reach $2.6 billion by 2032 through uptake in platinum-resistant disease and potential label expansion. The primary endpoint miss delays regulatory approval in the platinum-sensitive setting and underscores the restrictive addressable population due to reliance on high FRα expression.
